PQR309 is a novel dual PI3K/mTOR inhibitor with antitumor pre-clinical activity in lymphomas as single agent and in combination

ABSTRACT: assess the efficacy of dual PI3K/mTOR inhibitor with anti-lymphoma activity as single agent and in combination

ORGANISM(S): Homo sapiens

PROVIDER: GSE94670 | GEO | 2019/01/24

SECONDARY ACCESSION(S): PRJNA371789

REPOSITORIES: GEO